Interim report January - September 2009

* The Group's sales for the period amounted to SEK 481 (412) million
* EBITDA amounted to SEK 75 (49) million
* EBIT amounted to SEK 58 (39) million
* The net profit after tax for the period amounted to SEK 16 (34)
  million*
* Earnings per share after tax for the period were SEK 0.05 (0.17 )
  before and after dilution*

Significant events during the period
* The capital acquisition implemented in Q2 is fully subscribed,
  bringing BioPhausia proceeds of
SEK 64 million before expenses.
* Generic product sales are launched in Poland in Q3.
* Novalucol is among the limited number of non-prescription drugs
  cleared for sale in the large
supermarket chains.
* Employees acquired 2,334,000 warrants in Q3 under the new incentive
  programme.

Period July-September
* The Group's sales for the quarter amounted to SEK 148 (159) million
* EBITDA amounted to SEK 21 (26) million
* Operating profit was SEK 15 (21) million
* Profit after tax amounted to SEK 1 (2) million
* Earnings per share after tax was SEK 0.00 (0.01) before and after
  dilution


Stockholm 20 of November 2009

CLAES THULIN
CHIEF EXECUTIVE OFFICER


FOR FURTHER INFORMATION
Claes Thulin CEO, +46-8-407 64 30
www.biophausia.se